PubRank

Claes Held

Author PubWeight™ 78.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 18.03
2 Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006 11.72
3 Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011 3.90
4 Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013 3.25
5 Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2011 3.20
6 Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014 2.90
7 Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009 2.85
8 Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. Eur Heart J 2013 2.10
9 Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011 1.98
10 Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2013 1.77
11 Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. Nephrol Dial Transplant 2007 1.67
12 Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. Eur Heart J 2013 1.56
13 Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. Eur Heart J 2013 1.55
14 Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 2010 1.53
15 Physical activity in patients with stable coronary heart disease: an international perspective. Eur Heart J 2013 1.53
16 Long-term effects of an expanded cardiac rehabilitation programme after myocardial infarction or coronary artery bypass surgery: a five-year follow-up of a randomized controlled study. Clin Rehabil 2010 1.49
17 Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011 1.33
18 Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem 2004 1.25
19 Evaluation of a web-based ECG-interpretation programme for undergraduate medical students. BMC Med Educ 2008 1.13
20 A high-fat meal is accompanied by increased plasma interleukin-6 concentrations. Nutr Metab Cardiovasc Dis 2006 1.10
21 Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail 2010 1.05
22 Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. Atherosclerosis 2006 1.00
23 Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. Eur J Prev Cardiol 2012 0.93
24 Effects of expanded cardiac rehabilitation on psychosocial status in coronary artery disease with focus on type D characteristics. J Behav Med 2007 0.92
25 Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2013 0.91
26 Genetic and environmental influences on the plasma interleukin-6 concentration in patients with a recent myocardial infarction: a case-control study. J Interferon Cytokine Res 2010 0.87
27 Do clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada? Eur Heart J Acute Cardiovasc Care 2013 0.86
28 The 2011 outcome from the Swedish Health Care Registry on Heart Disease (SWEDEHEART). Scand Cardiovasc J 2013 0.86
29 Prognostic value of plasma interleukin-6 concentrations and the -174 G > C and -572 G > C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis 2004 0.85
30 Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012 0.84
31 Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. J Hypertens 2002 0.83
32 Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention 2015 0.79
33 Genotype-specific increase in plasma concentrations of activated coagulation factor VII in response to experimental inflammation. A link between infection and acute myocardial infarction? Thromb Haemost 2005 0.78
34 Differential index: a simple time domain heart rate variability analysis with prognostic implications in stable angina pectoris. Cardiology 2008 0.77
35 Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J 2013 0.76
36 Improving long-term outcome after myocardial infarction. Lancet 2012 0.75
37 Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". Circulation 2014 0.75
38 Risk prediction in stable angina pectoris. Eur J Clin Invest 2012 0.75
39 Differential index, a novel graphical method for measurements of heart rate variability. Int J Cardiol 2005 0.75
40 Invasive strategies and outcomes for non-ST-segment elevation acute coronary syndromes: a twelve-year experience from SWEDEHEART. EuroIntervention 2016 0.75
41 [Riks-HIA will develop a new index for areas with room for improvement]. Lakartidningen 2012 0.75
42 EACPR country of the month initiative: Sweden. Eur Heart J 2015 0.75